2. Metabolic Enzyme/Protease Apoptosis
  3. ACSL Family Ferroptosis
  4. LIBX-A403

LIBX-A403 is a potent, selective and reversible ACSL4 inhibitor with a human IC50 of 0.049 μM and a Kd of 0.29 μM. LIBX-A403 binds in the ACSL4 fatty acid pocket in an ATP-dependent manner. LIBX-A403 prevents cell ferroptosis. LIBX-A403 can be used for the researches of cancer and parkinson's disease.

For research use only. We do not sell to patients.

LIBX-A403

LIBX-A403 Chemical Structure

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 Get quote
Solution
10 mM * 1 mL in DMSO Get quote
Solid
5 mg Get quote 2 - 4 weeks 1 - 3 weeks 3 - 5 weeks 1 - 3 weeks
10 mg Get quote 2 - 4 weeks 1 - 3 weeks 3 - 5 weeks 1 - 3 weeks
25 mg Get quote 2 - 4 weeks 1 - 3 weeks 3 - 5 weeks 1 - 3 weeks
50 mg Get quote 2 - 4 weeks 1 - 3 weeks 3 - 5 weeks 1 - 3 weeks
100 mg Get quote 2 - 4 weeks 1 - 3 weeks 3 - 5 weeks 1 - 3 weeks
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

LIBX-A403 Related Antibodies

Top Publications Citing Use of Products

View All ACSL Family Isoform Specific Products:

View All Isoforms
ACSL4 ACSL5

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

LIBX-A403 is a potent, selective and reversible ACSL4 inhibitor with a human IC50 of 0.049 μM and a Kd of 0.29 μM. LIBX-A403 binds in the ACSL4 fatty acid pocket in an ATP-dependent manner. LIBX-A403 prevents cell ferroptosis. LIBX-A403 can be used for the researches of cancer and parkinson's disease[1].

IC50 & Target

ACSL4

 

In Vitro

LIBX-A403 inhibits hACSL4 with an IC50 of 0.049 μM and a Kd of 0.29 μM and no activity against ACSL3 at concentrations up to 50 μM[1].
LIBX-A403 (18 h pretreatment) potently inhibits RSL3 (HY-100218A)-induced ferroptosis in MDA-MB-231 cells with an EC50 of 172 nM and no cytotoxicity up to 25 μM[1].
LIBX-A403 (10 μM; 2 h) engages with endogenous ACSL4 in MDA-MB-231 cells, as confirmed by increased thermal stability of the protein[1].
LIBX-A403 (2.5 μM; 4 h pretreatment) significantly inhibits Arachidonic acid (HY-109590) + Fe-induced ferroptosis and reduces lipid peroxidation in LUHMES dopaminergic neurons[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

LIBX-A403 Related Antibodies

Western Blot Analysis[1]

Cell Line: MDA-MB-231 human breast cancer cell
Concentration: 10 μM
Incubation Time: 2 h
Result: Increased the thermal stability of ACSL4, as evidenced by higher levels of soluble ACSL4 protein at elevated temperatures compared to DMSO-treated controls.

Cell Viability Assay[1]

Cell Line: LUHMES human dopaminergic neuron
Concentration: 2.5 μM
Incubation Time: 4 h (pretreatment); 48 h (AA+Fe exposure)
Result: Significantly protected LUHMES cells from AA+Fe-induced ferroptosis, with a marked reduction in lipid peroxidation compared to untreated ferroptosis-induced cells.
Showed protection comparable to that achieved with ACSL4 siRNA.
Molecular Weight

363.36

Formula

C21H17NO5
Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(C1=C(C2=CC(/C=C/C(OC)=O)=CC=C2O1)NC(C)=O)C3=CC=CC=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 50 mg/mL (137.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7521 mL 13.7605 mL 27.5209 mL
5 mM 0.5504 mL 2.7521 mL 5.5042 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (6.88 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7521 mL 13.7605 mL 27.5209 mL 68.8023 mL
5 mM 0.5504 mL 2.7521 mL 5.5042 mL 13.7605 mL
10 mM 0.2752 mL 1.3760 mL 2.7521 mL 6.8802 mL
15 mM 0.1835 mL 0.9174 mL 1.8347 mL 4.5868 mL
20 mM 0.1376 mL 0.6880 mL 1.3760 mL 3.4401 mL
25 mM 0.1101 mL 0.5504 mL 1.1008 mL 2.7521 mL
30 mM 0.0917 mL 0.4587 mL 0.9174 mL 2.2934 mL
40 mM 0.0688 mL 0.3440 mL 0.6880 mL 1.7201 mL
50 mM 0.0550 mL 0.2752 mL 0.5504 mL 1.3760 mL
60 mM 0.0459 mL 0.2293 mL 0.4587 mL 1.1467 mL
80 mM 0.0344 mL 0.1720 mL 0.3440 mL 0.8600 mL
100 mM 0.0275 mL 0.1376 mL 0.2752 mL 0.6880 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

LIBX-A403 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

LIBX-A403ACSL FamilyFerroptosisparkinson's diseaseMDA-MB-231 cellsferroptosiscancerfatty acid pocketACSL3ACSL4hACSL4LUHMES dopaminergic neuronsATPInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
LIBX-A403
Cat. No.:
HY-175328
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.